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Abstract
Epidermal Growth Factor Receptor (EGFR) is frequently over-expressed in head and neck 
squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor 
contributes to tumor growth. EGFR variant III (EGFRvIII) is the most commonly altered form of 
EGFR and contains a truncated ligand-binding domain. We previously reported that EGFRvIII is 
expressed in up to 40% of HNSCC tumors where it is associated with increased proliferation, 
tumor growth and chemoresistance to anti-tumor drugs including the EGFR targeting monoclonal 
antibody cetuximab. Cetuximab was FDA-approved in 2006 for HNSCC but has not been shown 
to prevent invasion or metastasis. The present study was undertaken to evaluate the mechanisms of 
EGFRvIII-mediated cell motility and invasion in HNSCC. We found that EGFRvIII induced 
HNSCC cell migration and invasion in conjunction with increased STAT3 activation, which was 
not abrogated by cetuximab treatment. Further investigation demonstrated that EGF-induced 
expression of the STAT3 target gene HIF1-α, was abolished by cetuximab in HNSCC cells 
expressing wild-type EGFR under hypoxic conditions, but not in EGFRvIII-expressing HNSCC 
cells. These results suggest that EGFRvIII mediates HNSCC cell migration and invasion via 
increased STAT3 activation and induction of HIF1-α, which contribute to cetuximab resistance in 
EGFRvIII-expressing HNSCC tumors.
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Introduction
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that regulates 
crucial cellular signaling pathways contributing to tumor progression. EGFR is frequently 
amplified and over-expressed in several human solid tumors including in a high percentage 
of head and neck squamous cell carcinomas (HNSCC). EGFR overexpression in HNSCC 
has been correlated with tumor progression, resistance to conventional therapy and poor 
prognosis (Grandis and Tweardy, 1993). Preclinical studies demonstrated the anti-tumor 
effects of EGFR targeting and the FDA approved the EGFR monoclonal antibody cetuximab 
for clinical use in HNSCC based on the results of a phase III trial (Bonner et al., 2006). 
However, while combining EGFR targeting with radiation prolonged overall survival, it did 
not reduce the incidence of metastasis. Despite the nearly ubiquitous expression of EGFR in 
HNSCC, there is only a 13% response rate when cetuximab is administered as a single agent 
(Vermorken et al., 2007). The tumor features that contribute to resistance to EGFR targeting 
are incompletely understood.
Receptor alterations that influence ligand and antibody binding may play a role in 
therapeutic resistance. The most common EGFR alteration in several cancers, including 
HNSCC, consists of a truncation in the extracellular domain known as EGFR variant III 
(EGFRvIII). This mutation eliminates exons 2-7 resulting in a distorted ligand-binding 
region (Bigner et al., 1990; Sugawa et al., 1990). EGFRvIII does not bind ligand but is 
constitutively activated in a ligand-independent manner. The presence of EGFRvIII in 
human tumors has been associated with tumor growth, metastasis, and survival in several 
malignancies including glioma, carcinomas of the breast, lung and HNSCC (Pedersen et al., 
2001). Furthermore, EGFRvIII has been reported to increase resistance to anti-tumor agents 
including EGFR inhibitors (Sok et al., 2006).
We previously reported the expression of EGFRvIII in up to 42% of HNSCC where co-
expression of EGFRvIII with wild-type EGFR increased HNSCC cell proliferation in vitro 
and tumor volume in vivo. Moreover, EGFRvIII decreased HNSCC cell apoptosis in 
response to cisplatin and decreased growth inhibition following treatment with cetuximab 
(Sok et al., 2006). While these results support the role of EGFRvIII in mediating tumor 
growth in response to EGFR targeting, the contribution of EGFRvIII to invasion and the 
precise downstream pathways that are induced by EGFRvIII are incompletely understood. 
EGFRvIII expression in glioma has been reported to correlate with expression of 
phosphotyrosine STAT3 (Mizoguchi et al., 2006). The lethality of HNSCC is associated 
with the tendency of these cancers to invade surrounding structures and metastasize. The 
present study was undertaken to test the hypothesis that EGFRvIII induces HNSCC invasion 
and subsequently, metastasis via activation of STAT3 signaling.
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Results
Expression of EGFRvIII in engineered HNSCC cells
We previously reported that EGFRvIII is expressed in approximately 40% of HNSCC 
tumors (Sok et al., 2006). For reasons that are incompletely understood, expression of 
EGFRvIII in human tumors is routinely lost in tissue culture (Bigner et al., 1990). 
Therefore, to study the consequences of EGFRvIII in HNSCC, we stably transfected EGFR 
vIII into a representative HNSCC cell line (UM-22B) as described previously (Nishikawa et 
al., 1994; Sok et al., 2006). Four independent clones that stably expressed EGFRvIII were 
isolated (vIII-1 to 4) as well as four vector-transfected control clones (control-1 to 4). Due to 
the high level of wild-type EGFR in HNSCC cell lines and tissues, commercially available 
EGFR antibodies that are reported to detect both EGFRvIII and wild-type EGFR in other 
tumor systems, are unable to identify EGFRvIII expression in HNSCC. Expression of the 
EGFRvIII transcript was therefore determined by RT-PCR where the rodent fibroblasts 
stably expressing wild-type EGFR (NR6W) or EGFRvIII (NR6M) were used as controls for 
EGFR and EGFRvIII, respectively. EGFRvIII gene expression was detected in all four vIII 
clones but not in vector-transfected control clones while wild-type EGFR gene expression 
was observed in both control and vIII clones (Figure 1A). Flow cytometry was also 
performed to measure the degree of expression of EGFRvIII in these clones. FACS analyses 
of the cell surface EGFRvIII receptor expression revealed no EGFRvIII in the vector 
transfected control cells and approximately 104 EGFRvIII receptors per cell in each of the 
HNSCC clones (Figure 1B). In addition, using flow cytometry we determined the number of 
EGFR receptors to be 1.61 × 105 receptors per cell (Supplemental Figure 1). Thus, the 
numbers of wild-type EGF receptors are 10-fold higher than EGFRvIII in the EGFRvIII- 
transfected clones. These results are consistent with findings in human HNSCC where all 
HNSCC tumors that express EGFRvIII also express wild-type EGFR, with a higher level of 
wild-type EGFR compared to EGFRvIII (Sok et al., 2006).
EGFRvIII increases HNSCC motility and invasion
We previously reported that EGFRvIII induces HNSCC cell proliferation in vitro and tumor 
growth in vivo (Sok et al., 2006). EGFRvIII has been shown to induce motility in murine 
fibroblasts (Pedersen et al., 2004). To determine the consequences of EGFRvIII on 
directional HNSCC cell motility, cell migration (wound-healing) assays were performed. 
Briefly, a wound was created in a confluent monolayer of HNSCC cells. Images captured at 
the creation of the wound and at the end of the assay were analyzed to measure the distance 
traveled by the leading edge of the cells in the wound. As shown in Figure 2A, HNSCC cell 
migration was increased in all four EGFRvIII-expressing clones compared to a vector-
transfected control (p=0.03). In order to validate these findings in other HNSCC cell lines, 
we transiently transfected 1483 and PCI-37A cells with an EGFR vIII expression plasmid 
and tested the migration of the cells in a transwell migration assay. EGFR vIII expressing 
cells demonstrated increased migration (Supplemental Figure 2A). We next assessed the 
consequences of EGFRvIII on HNSCC cell invasion through Matrigel, controlling for 
proliferation. As shown in Figure 2B, EGFRvIII-expressing HNSCC cells were significantly 
more invasive than vector transfected controls (p=0.03).
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Cetuximab was FDA-approved for the treatment of HNSCC in 2006. We previously 
reported that HNSCC cells expressing EGFRvIII are relatively resistant to the growth 
inhibitory effects of cetuximab in vitro and in vivo (Sok et al., 2006). Since the addition of 
cetuximab to radiation did not prevent metastasis in HNSCC patients, we next determined 
the effects of cetuximab on EGFRvIII-mediated invasion (Bonner et al., 2006). As shown in 
Figure 2C, while cetuximab abrogated EGF-induced invasion of vector control-transfected 
HNSCC cells, treatment of EGFRvIII-expressing HNSCC cells with cetuximab failed to 
decrease invasion. While EGF induced invasion of vector-transfected control cells, EGF 
treatment had no significant effect on the invasive capacity of EGFRvIII cells, which are 
more invasive than controls in the absence of growth factor stimulation. These results 
suggest that EGFRvIII induces HNSCC cell motility and invasion in vitro, which are not 
abrogated by treatment with the only clinically approved EGFR targeting strategy in 
HNSCC.
EGFRvIII increases STAT3 activation
The precise signaling pathways induced by EGFRvIII in the setting of cancer cells that also 
express wild-type EGFR are incompletely understood. STAT3 is activated downstream of 
several receptor and non-receptor tyrosine kinases including EGFR. A correlation between 
EGFRvIII expression and expression of phosphotyrosine STAT3 has been noted in 
glioblastomas (Mizoguchi et al., 2006). We previously reported that STAT3 is activated 
downstream of wild-type EGFR in HNSCC (Grandis et al., 1998). To determine whether 
STAT3 is differentially activated by EGFRvIII, we analyzed expression of tyrosine 
phosphorylated STAT3 by immunoblotting in addition to STAT3 transcriptional activity in 
the EGFRvIII-expressing HNSCC cells compared with vector-controls. As shown in Figure 
3A, phosphotyrosine STAT3 was expressed at higher levels in HNSCC cells that contain 
EGFRvIII compared to vector-transfected controls. Transiently transfected HNSCC cells 
1483 and PCI-37A also demonstrated higher levels of phosphorylated STAT3 
(Supplemental Figure 2B). In addition, EGFRvIII-expressing HNSCC cells demonstrated 
increased STAT3 transcriptional activity using an hSIE luciferase reporter assay compared 
with controls (p=0.03) (Figure 3B). To determine the relative expression levels of 
phosphorylated and total STAT3 in EGFRvIII-expressing HNSCC tumors, xenografts 
derived from EGFRvIII-expressing cells were analyzed. As shown in Figure 3C, EGFRvIII-
expressing tumors contained higher levels of phosphorylated STAT3 compared to tumors 
derived from vector-transfected control cells (p=0.03). Further, EGFRvIII expression was 
associated with increased tumor growth in a xenograft model, thus confirming our previous 
findings (Sok et al., 2006) (data not shown). To determine the effects of cetuximab on 
EGFRvIII-mediated STAT3 activation, HNSCC cells expressing EGFRvIII were treated 
with cetuximab followed by STAT3 promoter assays. While cetuximab decreased STAT3 
promoter activity in vector-transfected control cells cetuximab was unable to abrogate 
STAT3 activation in HNSCC cells expressing EGFRvIII (Figure 3D). Similarly, EGF 
increased STAT3 promoter activity in vector-transfected controls, while EGF was unable to 
augment the already elevated levels of STAT3 promoter activation in HNSCC cells 
expressing EGFRvIII. These results indicate that EGFRvIII enhances STAT3 transcription 
and phosphorylation in HNSCC, effects that are resistant to treatment with cetuximab.
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STAT3 is required for EGFRvIII-mediated motility and invasion
STAT3 has been implicated in several oncogenic processes including proliferation, survival, 
and invasion and may represent a therapeutic target for cancer (Germain and Frank, 2007). 
To determine whether STAT3 is required for EGFRvIII-mediated cell motility and invasion, 
we performed wound healing and invasion assays in the presence or absence of siRNA 
targeting STAT3, under conditions where siRNA did not modulate proliferation. In order to 
examine the phenotypic effects of EGFR vIII signaling via STAT3, we assessed cell 
invasion and migration in the absence of EGFR ligand. STAT3 siRNA effectively abrogated 
STAT3 levels in vector control and EGFR vIII expressing cells (Figure 4A). As shown in 
Figures 4B and 4C, knockdown of STAT3 (and phosphotyrosine STAT3) reduced the 
motility and invasion of EGFRvIII-expressing HNSCC cells, under conditions controlling 
for proliferation (p=0.03). In fact, on STAT3 knockdown, the degree of wound healing and 
invasion in the EGFRvIII cells were comparable to levels in vector-transfected controls. In 
addition to downmodulation of STAT3 expression using siRNA, we also blocked STAT3 in 
the cells with a transcription factor decoy directed against STAT3 as described previously 
(Leong et al., 2003). The STAT3 decoy interferes with STAT3-mediated DNA binding and 
abrogates STAT3 target gene expression. As shown in Figures 4D and 4E, treatment with 
the STAT3 decoy resulted in reduction of both migration and invasion in vIII-4 cells 
compared to treatment with a mutant control decoy, under conditions where the decoy did 
not affect cell growth. In the absence of EGFR ligand there was no significant reduction in 
the migration or invasion of control cells treated with the STAT3 decoy (p=0.19). However, 
the STAT3 decoy significantly abrogated the migration and invasion of EGFRvIII 
expressing HNSCC cells compared to the control cells (p=0.03 and p=0.048, respectively).
Others have reported that PI3K/AKT is activated downstream of EGFRvIII in glioma 
(Antonyak et al., 1998; Li et al., 2004). To determine whether motility and invasion are also 
mediated by this pathway, in addition to STAT3, we examined the expression of AKT 
phosphorylation in EGFRvIII and vector-transfected control HNSCC cells and found that 
similar to results in previous reports, EGFRvIII-expressing HNSCC cells expressed 
increased levels of pAKT (Figure 5A). However, in contrast to our observations with 
STAT3 targeting, blockade of PI3K/AKT using the pharmacologic inhibitor LY294002 
abrogated cell growth but not invasion, in HNSCC cells expressing EGFRvIII (Figures 5B-
C). Similar results were also obtained using siRNA directed against the p85 subunit of PI3K 
(data not shown). These results suggest that STAT3 is specifically required for the 
EGFRvIII-mediated enhancement of HNSCC cell motility and invasion.
Cetuximab does not abrogate EGFRvIII-induced HIF-1α expression under hypoxic 
conditions
Solid tumors, including HNSCC, contain large regions of low oxygen concentrations 
(hypoxic) regions, which contribute to resistance to treatment with standard approaches 
including chemotherapy and radiation. Hypoxia potently induces expression of hypoxia 
inducible factor (HIF-1α), which has been shown to be a STAT3 target gene (Niu et al., 
2008). EGFRvIII has been reported to contribute to hypoxia-mediated tumor growth in 
conjunction with radiation therapy but has not been previously linked to HIF-1α expression 
(Weppler et al., 2007). We therefore examined the expression of HIF-1α following 
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treatment of HNSCC cells expressing EGFRvIII (or vector-transfected controls) with EGF 
and/or cetuximab. As shown in Figure 6, hypoxia-induced expression of HIF-1α was 
abrogated by cetuximab in vector-transfected control cells but not in HNSCC cells 
expressing EGFRvIII. These results suggest that STAT3 signaling via HIF-1α may 
contribute to cetuximab resistance in EGFRvIII-expressing HNSCC tumors under hypoxia.
Discussion
We previously reported that EGFRvIII is expressed in up to 40% of HNSCC tumors where 
expression of this altered receptor mediates growth and resistance to chemotherapy or EGFR 
targeting using cetuximab (Sok et al., 2006). Patients with HNSCC succumb to their disease 
due to invasion into surrounding tissues and regional and distant metastasis. Although the 
addition of cetuximab to radiation was shown to improve survival, it did not decrease 
metastasis (Bonner et al., 2006). The present study was undertaken to determine the effects 
of EGFRvIII on the migration and invasion of HNSCC cells and the signaling pathways that 
mediate these properties. Our results suggest that EGFRvIII increases HNSCC motility and 
invasion, at least in part, through activation of STAT3.
EGFRvIII is the most common EGFR alteration in human cancers. Deletion of exons 2-7 
gives rise to a receptor that lacks a ligand binding site and is constitutively activated in a 
ligand-independent manner. EGFRvIII has not been observed in normal tissue, but it has 
been detected in carcinomas of the brain, breast, ovary (Moscatello et al., 1995), lung 
(Garcia de Palazzo et al., 1993), prostate (Olapade-Olaopa et al., 2000) and head and neck 
(Sok et al., 2006). Expression of EGFRvIII has been correlated with poor prognosis in brain 
tumors (Diedrich et al., 1995). Further, EGFRvIII can to transform fibroblasts in vitro 
(Pedersen et al., 2004) and enhance the tumorigenicity of cancer cells in vivo, supporting its 
oncogenic function (Tang et al., 2000).
The effect of EGFRvIII on tumor cell behavior is incompletely understood. Nagane et al. 
reported that EGFRvIII-expressing cells demonstrated less apoptosis in response to cisplatin 
treatment (Nagane et al., 1998). Others have reported that EGFRvIII induced glioma cell 
migration and invasion via induction of metalloproteases and extracellular matrix 
components (Lal et al., 2002); (Cai et al., 2005). The precise signaling events that mediate 
EGFRvIII-induced migration and invasion need further investigation. Moscatello et al. 
reported that EGFRvIII activates PI3-K pathway instead of the Ras-Raf-MEK pathway, 
which is preferentially activated by wild-type EGFR (Moscatello et al., 1998). Further 
investigation suggested that constitutive PI3-K/AKT activation by EGFRvIII may contribute 
to chemoresistance and radioresistance in these cells (Li et al., 2004; Narita et al., 2002). 
Antonyak et al. showed that c-Jun N-terminal Kinase (JNK) was constitutively activated by 
EGFRvIII and was down-regulated by PI3-K inhibition (Antonyak et al., 1998). To date, 
signaling through PI3-K/AKT has not been correlated with tumor cell migration or invasion 
mediated by EGFRvIII. We found that although EGFRvIII-expressing HNSCC cell 
expressed increased levels of phosphorylated AKT, abrogation of PI3-K/AKT using either 
LY294002 or p85 siRNA, did not abrogate invasion in EGFRvIII-expressing HNSCC cells. 
LY294002 treatment decreased the proliferation of EGFRvIII-expressing HNSCC cells, 
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suggesting that activated PI3K/AKT by EGFRvIII contributes to EGFRvIII-induced 
HNSCC cell proliferation, but not invasion (Figure 5).
There are few, but conflicting, reports linking EGFRvIII to STAT3 signaling. While 
Mizoguchi et al. reported a correlation of expression levels of EGFRvIII and 
phosphotyrosine STAT3 in glioblastoma (Mizoguchi et al., 2006), Andersen et al. recently 
reported that glioma cells that express EGFRvIII fail to induce IRF-1 via STAT3 
phosphorylation (Andersen et al., 2008). Cumulative evidence has implicated STAT3 as an 
critical oncogene where elevated expression levels of tyrosine phosphorylated STAT3 are 
detected in numerous human cancers (Bowman et al., 2000). Studies in HNSCC 
demonstrate that STAT3 is activated downstream of receptor and non-receptor tyrosine 
kinases including EGFR and Src family kinases as well as IL-6/gp130 (Kijima et al., 2002), 
(Xi et al., 2003), (Sriuranpong et al., 2003). Targeting STAT3 in HNSCC preclinical 
HNSCC models inhibited tumor growth but not the growth of normal epithelial cells (Leong 
et al., 2003). Expression of tyrosine phosphorylated STAT3 in the primary HNSCC tumor 
has been correlated with nodal metastasis, advanced tumor stage and decreased survival 
(Masuda et al., 2002). The results of the present study suggest that activation of STAT3 
downstream of EGFRvIII in HNSCC contributes to the increased migration and invasion.
STAT3 target genes include cell cycle regulators (Sinibaldi et al., 2000), anti-apoptotic 
genes (Oritani et al., 1999) and pro-angiogenic factors (Huang et al., 2002), each of which 
has been implicated in tumorigenic processes including invasion and metastasis. STAT3 has 
been shown to contribute to cancer migration and invasion thorough regulation of genes that 
stimulate these processes including matrix metalloproteinases (e.g. MMP-2 and MMP-9), 
VEGF and/or bFGF (Dechow et al., 2004); (Qiu et al., 2007). In addition to the 
transcriptionally mediated effects of STAT3 on cell migration and invasion, transcription-
independent pathways have also been described for the effects of STAT3 on cell motility. 
Specifically, STAT3 has been found to directly interact with cell motility components such 
as focal adhesion components, FAK, paxillin (Silver et al., 2004), p130CAS (Kira et al., 
2002), or cytoskeltal microtubles (Ng et al., 2006). We did not detect increased expression 
of MMP-2, MMP-9 or VEGF in association with the EGFRvIII-mediated migration and 
invasion observed in these cells (data not shown), suggesting that other STAT3 target genes 
or STAT3 interacting proteins may be playing a role. Additionally, the lack of HIF-1α 
decrease in EGFRvIII cells treated with cetuximab under hypoxic conditions suggests a 
more complex regulatory balance between oxygen-dependent and –independent factors that 
influence HIF-1α.
Aberrant activation of STAT3 has been shown to contribute to tumor progression making 
STAT3 an attractive therapeutic target. To date, no STAT3 targeting strategies have 
undergone clinical evaluation. We have developed a highly specific transcription factor 
decoy approach to block STAT3 signaling and demonstrated that it inhibits tumor growth in 
vitro and in vivo in HNSCC preclinical models (Leong et al., 2003). Using the same STAT3 
decoy, others have reported antitumor effects in a murine model of cutaneous squamous cell 
carcinoma (Sano et al., 2005). Toxicology studies in non-human primates were recently 
completed and demonstrated no evidence of toxicity (Sen et al., 2008). In the present study, 
treatment of EGFRvIII-expressing HNSCC cells with the STAT3 decoy abrogated cell 
Suzuki et al. Page 7
Oncogene. Author manuscript; available in PMC 2011 March 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
motility and invasion. These results suggest that selective activation by EGFRvIII in 
HNSCC contributes to the invasive phenotype, which can potentially be targeted with 
therapeutic strategies that inhibit STAT3. In addition to the decoy, others have reported the 
use of siRNA, peptidomimetic strategies, and G-quartet oligonucleotides to inhibit STAT3 
in cancer models (Leeman et al., 2006).
These cumulative results suggest that STAT3 activation is critical for cancer progression 
mediated by both wild-type EGFR and EGFRvIII, which are often co-expressed in HNSCC 
tumors (Sok et al., 2006). Knockdown or blockade of STAT3 preferentially abrogated the 
migration and invasion of HNSCC cells that expressed EGFRvIII implicating STAT3 as a 
critical pathway in mediating HNSCC invasion in tumors that express this altered receptor. 
HNSCC cells co-express the wild-type and mutant EGFRvIII receptors with an estimated 
1.6 × 105 wild-type receptors (Supplemental Figure 1) and ~104 mutant EGFRvIII receptors 
per cell. Thus, in the presence of EGF, EGFRvIII-expressing HNSCC cells invade despite 
STAT3 knockdown (Supplemental Figure 3). We have previously demonstrated that both 
PLCγ-1 and c-Src mediate HNSCC invasion downstream of EGFR (Thomas 2003, Zhang 
2004). Thus EGF stimulation in cells expressing both EGFR and EGFR vIII likely results in 
invasion via multiple downstream signaling molecules including STAT3.
Therapeutic agents with selective activity against EGFRvIII are presently under clinical 
investigation including the immunotoxin MR1-1, the chimeric antibody 806 (Li et al., 2007) 
and irreversible HER1/HER2 inhibitors (Ji et al., 2006) that appear to have selective activity 
against EGFRvIII. The EGFR monoclonal antibody cetuximab is the only FDA-approved 
EGFR targeting strategy for HNSCC. We previously reported that HNSCC xenografts 
expressing EGFRvIII were resistant to the growth inhibitory effects of cetuximab (Sok et al., 
2006). Here we demonstrate that EGFRvIII cells are resistant to anti-invasive effects of 
cetuximab in HNSCC. Further, EGFRvIII expression results in an increase in 
phosphorylation of STAT3 in HNSCC cells. These results suggest that HNSCC tumors that 
express EGFRvIII may be best treated with strategies that selectively block EGFRvIII, or its 
downstream signaling pathways, in addition to targeting wild-type EGFR.
Materials and Methods
Cell lines, reagents, and cell culture
C225/cetuximab was purchased from the research pharmacy at the University of Pittsburgh 
Cancer Institute. For in vitro cell stimulation, recombinant human EGF (Sigma Chemical 
Co.) was used. Phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 was obtained from 
Calbiochem (San Diego, CA). NR6 (Swiss 3T3 murine fibroblasts) cells expressing 
EGFRwt (NR6W) were a generous gift from Dr. Alan Wells (University of Pittsburgh 
School of Medicine). NR6 cells expressing human EGFRvIII (NR6M) were generated as 
described previously (Batra et al., 1995). EGFRvIII-transfected HNSCC cells (vIII-1 to 4) 
and vector control transfected HNSCC cells (control-1 to 4) were generated as descried 
previously (Sok et al., 2006). All cells were maintained in DMEM (Mediatech, Inc., 
Herndon, VA) with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA) and 
incubated at 37°C in the presence of 5% CO2. To establish hypoxic conditions (1% O2), 
cells were placed in an InVivo300 hypoxia workstation (Ruskinn Life Sciences Ltd, UK).
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RT-PCR analysis and cDNA sequencing of EGFRvIII
Total RNA was isolated from HNSCC cell lines (5 × 106 cells) using Trizol (Invitrogen, 
Carlsbad, CA) according to the manufacturer's protocol. Total RNA (1 μg) was reverse-
transcribed with the first-strand cDNA synthesis using SuperScript First-Strand Synthesis 
System for RT-PCR (Invitrogen, Carlsbad, CA). To detect the deleted region of EGFRvIII, 
standard RT-PCR was performed as described previously (Sok et al., 2006).
Flow cytometry
Indirect analytic flow cytometry was done on a Becton Dickinson FACS calibur equipped 
with CellQuest Pro software (Becton Dickinson, San Jose, CA ). Assays were done at 4°C; 
all washes were done with iced medium to facilitate the detection of cell surface receptors 
without allowing internalization to occur. All profiles were obtained with cells maintained in 
ice-cold 1% bovine serum albumin/PBS. The percentage of a population designated as 
positive was arbitrarily defined as that region in which only the highest fluorescing 10% of 
the isotype-control stained cells graphed, corrected for background; this is a conservative 
estimate of the total positive staining population. In order to examine the cell surface 
expression of EGFRvIII proteins, target cultured cells were stained with anti-EGFRvIII 
monoclonal antibody L8A4 under nonpermeabilized conditions. Subconfluent cells were 
detached from culture flasks by incubation with 0.02% EDTA/PBS; 106 cells were 
maintained in 0.5% paraformaldehyde/ PBS for 10 minutes at 4°C, washed, resuspended in 
150 mL PBS containing 10% fetal bovine serum, and blocked for 20 minutes at 4°C. After 
two washes, the samples were reacted with L8A4 monoclonal antibody (10 mg/mL, black 
line) and irrelevant mouse IgG1k (10 mg/mL, solid gray) in PBS for 60 min. After two 
additional washes, cells were incubated with FITC-labeled secondary antibody for 30 
minutes at 4°C and analyzed on a Becton Dickinson FACS calibur instrument (Becton 
Dickinson).
Western blotting
Cell lines were lysed in detergent containing 1% NP40, 0.1 mM phenylmethylsulfonyl 
fluoride, 1 mg/ml leupeptin, and 1 mg/ml aprotinin, and protein levels were determined 
using the Bio-Rad protein assay method (Bio-Rad Laboratories, Hercules, CA). Forty μg of 
total protein were separated on 8% SDS-PAGE gels and transferred to nitrocellulose 
membranes using the semi-dry transfer machine (BioRad Laboratories, Hercules, CA). 
Membranes were blocked with 5% skim milk/Tris-buffered saline with Tween 20 () solution 
for 2 hour at room temperature, and incubated with primary antibodies in 5% skim milk in 
TBS-T overnight at 4°C. After washing with TBS-T three times, membranes were incubated 
for 1 hour with HRP-conjugated secondary antibody (Bio-Rad Laboratories, Hercules, CA) 
1:3000 diluted in 5% skim milk in TBS-T. The filters were rinsed with TBS-T three times, 
and the blot was developed using Luminol Regent (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) by autoradiography. Antibodies used for blotting included β-actin (Oncogene 
Research Products, Boston, MA), β-tubulin (Abcam, Cambridge, UK), HIF-1α (BD 
Transduction Laboratories, San Jose, CA), phospho-AKT (Ser473), AKT, phospho-STAT3 
(Tyr705) and STAT3 (Cell Signaling Technology, Beverly, MA).
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Luciferase reporter assay
HNSCC cells (4 × 105/ml) were plated onto 6-well tissue culture plates. After sixteen hours 
incubation, cells were transiently co-transfected with pSTAT3TALuc, a generous gift from 
Dr. Jacqueline Bromberg (Memorial Sloan-Kettering Cancer Center, New York, NY) and 
pRL-TK (Promega, Madison, WI) a Renilla luciferase construct, using Lipofectamine 2000 
(Invitrogen) according to the manufacturer's instructions (Besser et al., 1999). The 
transfection media was replaced to complete DMEM after 4 h of transfection. Cells were 
lysed and luciferase assays were performed 24h after the transfection using the Dual-
Luciferase Reporter Assay System kit (Promega, Madison, WI). Cell lysates were subjected 
to protein estimation using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, 
CA). Relative light units (RLU) from luciferase was normalized to RLU from renilla 
luciferase (to account for differences in transfection efficiency) and to micrograms of 
protein (to account for differences in protein concentrations between samples).
Matrigel invasion assay
Cell invasion was evaluated in vitro using Matrigel-coated semi-permeable modified 
Boyden inserts with a pore size of 8 μm (Becton Dickinson/Biocoat, Bedford, MA). Cells 
were plated in triplicate at a density of 5 × 103 cells per well in DMEM in the insert. At the 
same time cells were plated in 96-well plates to serve as loading controls. Both the insert 
and the holding well were subjected to the same medium composition with the exception of 
serum. The insert contained no serum, whereas the lower well contained 10% fetal bovine 
serum (FBS) that served as a chemo-attractant. After 24 h of treatment at 37°C in a 5% CO2 
incubator, the cells in the insert were removed by wiping gently with a cotton swab. Cells on 
the reverse side of the insert were fixed and stained with Hema 3 (Fisher Scientific, 
Hampton, NH) according to the manufacturer's instructions. Cells plated in 96-well plates 
were subjected to MTT assays and the cell numbers across the groups were normalized. The 
number of invading cells was adjusted accordingly.
Wound healing assay
HNSCC cells were grown to confluence on 6-well tissue culture dishes and a single scrape 
was made in the confluent monolayer using a sterile pipette tip. The monolayer was washed 
with PBS and complete medium was added. Photographs were taken at 0 and 6 h, and the 
relative denuded area at the cellular front was determined by computer-assisted image 
analysis; markings on the plate ensured measurement of the same site for the photographs. 
The decreased area was then expressed as a percentage within each experiment, allowing 
direct comparisons between experiments.
STAT3 siRNA and STAT3 decoy transfection
The STAT3 decoy and the mutant control decoy sequences (double-stranded 
deoxyribonucleotides with phosphorothioate modifications in the first three bases and last 
three bases of the sequences) were generated as described previously (Leong et al., 2003). 
The mutant control decoy, carrying a single base mutation, that does not abrogate STAT3 
DNA binding activity, was used as a control as in previous studies (Leong et al., 2003; Xi et 
al., 2005). The siRNA sequences targeting STAT3 human mRNA (D-003544-01, sense 5’-
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CCAACGACCUGCAGCAAUAUU-3’, and antisense 5’-
PUAUUGCUGCAGGUCGUUGGUU-3’; Dharmacon, Lafayette, CO) were transfected into 
HNSCC cells for STAT3 silencing. The nontargeting siRNA (D-001210-01, sense 5'-
UAGCGACUAAACACAUCAAUU-3', antisense 5-
UUGAUGUGUUUAGUCGCUAUU-3'; Dharmacon) was used as a control. The siRNA or 
decoy transfections were performed using the Lipofectamine 2000 (Life Technologies Inc). 
In brief, HNSCC cells were plated (1.8 × 105/well for siRNA or 1.0 × 106/well for decoy 
transfection in a six-well tissue culture plate). Sixteen hours after plating, cells were 
transfected with 200 pmol of STAT3 siRNA or non-targeting control siRNA, or 12.6 pmol 
of STAT3 decoy or mutant control decoy. The transfection medium was replaced with 
complete DMEM after 4 h of transfection.
In vitro growth assay
To determine if the sensitivity of HNSCC cells to PI3K/AKT inhibition was affected by 
EGFRvIII expression, vector-transfected and EGFRvIII-expressing HNSCC cells (3 × 104) 
were seeded onto 6 well plates and treated with a PI3K inhibitor LY294002. Each cell 
population was then harvested in triplicate, transferred to a hemocytometer, and counted 
every other day over a period of 6 days.
In vivo growth of HNSCC cell expressing EGFRvIII and analysis of HNSCC xenografts
HNSCC cells [UM-22B-expressing EGFRvIII (vIII-4) or empty vector-transfected parental 
cells (control-1)] were cultured in DMEM containing 10% fetal bovine serum. Cells were 
trypsinized and washed 3 times with HBSS (Life Technologies, Carlsbad, CA). Cell number 
and viability were determined using trypan blue dye exclusion. A suspension of 3 × 106 
HNSCC cells in 50 μL HBSS was injected into floor of mouth of nu/nu athymic nude mice 
(n = 8 per cell line; Harlan Sprague-Dawley, Indianapolis, IN) transcutaneously. Tumor 
volumes were measured in two dimensions with vernier calipers and calculated using the 
formula: (length × width2) × 0.52. At the end of the study, mice were sacrificed by cervical 
dislocation under anesthesia the tumors surgically excised and snap frozen in dry ice. To 
evaluate the expression of phosphorylated and total STAT3 in HNSCC xenografts, tumors 
homogenized, sonicated in detergent containing 1% NP40, 0.1 mM phenylmethylsulfonyl 
fluoride, 1 mg/ml leupeptin, and 1 mg/ml aprotinin. Forty μg of total protein were separated 
on 8% SDS-PAGE gels and immunoblotted for phosphorylated and total STAT3 and β-
tubulin. Animal use and care was in strict compliance with institutional guidelines 
established by the Institutional Animal Care and Use Committee at the University of 
Pittsburgh.
Statistical analysis
For wound healing and invasion studies, the statistical significance of differences in the 
number of invading cells or migrated area were assessed by use of Wilcoxon-Mann-Whitney 
two-tailed exact test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. EGFRvIII expression in HNSCC-transfected cells
(A) EGFRvIII mRNA levels were examined in HNSCC-transfected cells (UM-22B) by RT-
PCR. Representative ethidium bromide-stained gel showing EGFR and EGFRvIII PCR 
products from four vector-transfected control clones (control 1-4) and EGFRvIII-expressing 
clones (vIII-1 to vIII-4). The EGFR-transfected NR6W cell line was used as positive control 
for EGFR and EGFRvIII-transfected NR6M cells served as positive control for EGFRvIII. 
Experiments were repeated 3 times with similar results. (B) Flow cytometry results for 
UM-22B clones stably transfected with EGFRvIII. Surface EGFRvIII on four HNSCC-
transfected clones (vIII-1 to vIII-4) were detected by flow cytometry. A vector-transfected 
control clone (control-1) was used as negative control. Data is represented as Mean 
Fluorescent Intensity. Experiments were repeated 3 times with similar results.
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Figure 2. EGFRvIII increases HNSCC migration and invasion
(A) The denuded area of vector control-transfected cells (control-1) and EGFRvIII-
expressing cells (vIII-1 to 4) was measured 0 h and 6 h after a single scrape (wound) was 
made in the confluent monolayer using a sterile pipette tip. The area covered by the 
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migrating cells was measured using computer-assisted image analysis. The decreased area 
was determined by subtracting the values obtained a 6 hr from the 0 hr time point. The fold-
decreased area in the EGFRvIII-transfected cells was compared with vector-transfected 
controls. Cumulative results are shown from four independent experiments (*p=0.03). (B) 
The invasive capacity of EGFRvIII-expressing cells (vIII-1 to -4) compared with a vector-
transfected control (control-1) was determined using a Boyden chamber Matrigel assay. The 
fold increase in invasion relative to vector-transfected control is shown. Cumulative results 
are shown from four independent experiments (*p=0.03). (C) EGFRvIII-expressing cells 
(vIII-4) and vector transfected control cells (control-1) were subjected to an invasion assay 
in the presence of EGF (10 ng/ml) and/or C225 (7 μg/ml) for 24 hours. The fold-increase in 
invasion relative to untreated vector-transfected control (control-1 NoTx) is shown. The 
invasion of EGFRvIII-expressing HNSCC cells was not abrogated by C225 treatment 
compared with vector-transfected control cells (*p=0.03).
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Figure 3. EGFRvIII increases STAT3 activation
(A) After serum starvation for 24 hours, cell extracts from vector-transfected control cells 
(control-1), EGFRvIII-transfected cells (vIII-1 and vIII-4) were analyzed by Western blot 
analysis. The blot was incubated with phosphotyrosine-STAT3 antibody, stripped and 
probed for total STAT3 and β-actin to ensure equivalent loading. The experiment was 
performed 3 times with similar results. (B) Vector-transfected control cells (control-1) and 
EGFRvIII cells (vIII-1 and vIII-4) were transiently co-transfected with a luciferase construct 
under the control of STAT3 responsive promoter and a Renilla luciferase construct, 
incubated in complete media for 24h and assayed for luciferase activity. The fire-fly 
luciferase activity units (RLU) were normalized to Renilla luciferase RLU and micrograms 
of total protein and expressed as a fold of the activity of the control in each experiment. 
Cumulative results from two independent experiments indicate a significant increase in 
STAT3 promoter activity in HNSCC cells expressing EGFR vIII (*p=0.05). (C) HNSCC 
xenografts derived from EGFRvIII-expressing cells and xenografts derived from vector-
transfected control cells were analyzed for phosphorylated and total STAT3 expression by 
immunoblotting. A representative immunoblot of pSTAT3 and STAT3 levels in control and 
vIII xenograft tumors are depicted. Densitometry analysis was performed on immunoblots 
from all tumors (n=8) and phosphorylated STAT3 expression levels relative to total STAT3 
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are shown as mean ± SE. EGFRvIII-expressing HNSCC cell xenograft tumor (n=8) 
expressed 2-fold higher levels of phosphorylated STAT3 compared to control HNSCC 
xenografts (n=8) (*p=0.027). (D) EGFRvIII-transfected cells (vIII-4) and vector-transfected 
control cells (control-1) were transiently co-transfected with a hSIE-luciferase construct and 
Renilla luciferase construct for 4 h. Cells were incubated in serum free media +/− EGF 
(10ng/ml) and/or cetuximab (C225) (0.7μg/ml ) for 24h and assayed for luciferase activity. 
The luciferase RLU were normalized to Renilla luciferase-RLU and to micrograms of total 
protein and expressed as a fold of the activity of the vector control (control-1, NoTx) in each 
experiment. Cumulative results are shown from two independent experiments. The hSIE 
promoter activity of EGFRvIII-expressing cells was not stimulated by EGF or abrogated by 
cetuximab treatment. In contrast, cetuximab effectively abrogated EGF induced STAT3 
promoter activity in HNSCC cells (*p=0.05).
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Figure 4. STAT3 plays a critical role in EGFRvIII-mediated migration and invasion
(A) EGFRvIII-expressing cells (vIII-4) and vector transfected control cells (control-1) were 
transfected with non-targeting siRNA or STAT3 siRNA for 4 h. Untreated cells (NoTx) and 
transfected cells were collected at hours 48 for the analysis of total STAT3 protein levels by 
immunoblotting. B-tubulin levels demonstrate equal loading of protein in all lanes. The 
experiment was repeated 4 times with similar results. (B) STAT3 siRNA decreases HNSCC 
migration and invasion. Forty eight hours after non-targeting or STAT3 siRNA transfection, 
EGFRvIII-transfected HNSCC cells (vIII-4) and vector-transfected controls (control-1) were 
subjected to migration (left panel) and invasion assays (right panel) with the same methods 
described in materials and methods. Both control cells and EGFRvIII expressing cells 
decreased their migration and invasion when cells are treated with STAT3 siRNA compared 
to non-targeting siRNA treated condition. (C) Percent reduction of migration and invasion 
with STAT3 siRNA in both control-1 and vIII-4 was calculated from the results shown in 
panel B. The degree of both migration (left panel) and invasion (right panel) with STAT3 
siRNA was greater in EGFRvIII expressing cells than in control cells (*p=0.03). (D) STAT3 
decoy decreases HNSCC migration and invasion. After mutant or STAT3 decoy treatment, 
EGFRvIII-expressing HNSCC cells (vIII-4) and vector-transfected controls (control-1) were 
subjected to migration (left panel) and invasion assays (right panel). Both control cells and 
EGFRvIII-expressing cells demonstrated decreased migration and invasion when treated 
with STAT3 decoy compared to mutant control decoy treatment. (E) Percent reduction of 
migration and invasion with STAT3 decoy in both control-1 and vIII-4 was calculated from 
the results shown in Figure 4D. HNSCC cells expressing EGFR vIII had significantly 
reduced migration (*p=0.03) and invasion (*p=0.048) compared to control cells in the 
presence of STAT3 decoy.
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Figure 5. Increased PI3K/AKT signaling in EGFRvIII-expressing HNSCC cells mediates 
proliferation, but not invasion
(A) EGFRvIII-expressing HNSCC cells express increased levels of phosporylated AKT. 
After serum starvation for 24 hours, cell extracts from vector-transfected control cells 
(control-1) and EGFRvIII-transfected cells (vIII-1 and vIII-4) were analyzed by Western 
blot analysis. The blot was incubated with phosphoserine-AKT antibody (Ser473), stripped 
and immunoblotted for total AKT and β-actin to ensure equivalent loading. The experiment 
was performed 3 times with similar results. (B) Blockade of PI3K/AKT abrogates cell 
growth in HNSCC cells expressing EGFRvIII. HNSCC cells expressing EGFRvIII and 
vector-transfected control cells were plated onto 6 well plates with presence (◆, vIII-4), (◇, 
control-1) or absence (■, vIII-4), (□, control-1) of 20μM of LY294002. Growth curve of the 
transfected cell lines were obtained by cell counting using vital dye exclusion at several time 
points for 6 days. HNSCC cells expressing EGFRvIII showed increased growth rates 
compared with the vector- transfected control cells where cell growth was abrogated by 
PI3K/AKT blockade in both cell lines. Representative results from 3 independent 
experiments are shown. (C) Cell invasion was not abrogated by PI3K/AKT blockade. Cell 
invasion assay was performed with HNSCC cells expressing EGFRvIII and vector-
transfected control cells with or without PI3K/AKT inhibition using 20μM of LY294002. 
HNSCC cells expressing EGFRvIII show increased cell invasion compared with the vector-
transfected control cells but cell invasive capacity was not decreased by PI3K/AKT 
blockade in either cell line.
Suzuki et al. Page 28
Oncogene. Author manuscript; available in PMC 2011 March 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. EGFRvIII induces HIF-1α expression under hypoxic conditions, which is not 
abrogated by ceutximab
EGFRvIII-expressing cells (vIII-4) and vector transfected control cells (control-1) were 
treated with (or without) EGF (10 ng/ml) and/or cetuximab (C225, 7 μg/ml) in under 
normoxic or hypoxic conditions for 24 h. Under hypoxic conditions and EGF treatment, 
EGFRvIII-expressing cells maintained expression of HIF-1α with cetuximab treatment 
whereas the expression of HIF-1α in vector-transfected control cells was significantly 
decreased by cetuximab (p=0.014). The experiment was performed 3 times with similar 
results.
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